Star Imaging

How has been the historical performance of Star Imaging?

Star Imaging has shown significant growth in shareholder's funds and total assets over the past four years, with shareholder's funds increasing to 47.15 Cr and total assets to 98.16 Cr by March 2025. Profit before tax improved to 21.00 Cr, although cash flow from operating activities turned negative, indicating potential cash generation challenges.

Answer:<BR>The historical performance of Star Imaging shows a significant increase in shareholder's funds and total assets over the past four years, with no standalone results declared. As of March 2025, shareholder's funds reached 47.15 Cr, up from 31.35 Cr in March 2024, and total assets also increased to 98.16 Cr from 81.64 Cr in the previous year. The company has seen a rise in total reserves, which grew to 33.65 Cr in March 2025 from 29.85 Cr in March 2024. Long-term borrowings decreased slightly to 14.87 Cr in March 2025 from 15.71 Cr in March 2024, while short-term borrowings increased to 17.86 Cr from 14.93 Cr in the same period. The profit before tax improved to 21.00 Cr in March 2025, compared to 16.00 Cr in March 2024, indicating a positive trend in profitability.<BR><BR>Breakdown:<BR>Star Imaging's financial metrics reflect a positive trajectory in its consolidated balance sheet and cash flow results. The company's shareholder's funds have shown a robust increase, rising from 18.36 Cr in March 2022 to 47.15 Cr in March 2025, while total assets have also grown significantly from 58.34 Cr to 98.16 Cr over the same period. Total reserves increased notably, indicating a strengthening financial position. Despite a slight decrease in long-term borrowings, short-term borrowings have risen, suggesting a shift in financing strategy. Profit before tax has improved markedly, moving from 0.00 Cr in March 2023 to 21.00 Cr in March 2025, showcasing enhanced operational performance. However, cash flow from operating activities turned negative in March 2025, indicating challenges in cash generation despite the overall growth in profitability.

Is Star Imaging overvalued or undervalued?

As of December 3, 2025, Star Imaging is considered overvalued with a valuation grade of expensive, a PE ratio of 13.80, and strong returns on capital, despite a recent stock price decline and better valuations compared to peers like Max Healthcare and Apollo Hospitals.

As of 3 December 2025, Star Imaging's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 13.80, an EV to EBITDA of 8.67, and a ROE of 33.81%. In comparison to peers, Max Healthcare has a significantly higher PE ratio of 74.7, while Apollo Hospitals is at 61.84, highlighting that Star Imaging's valuation is more reasonable yet still on the higher side.<BR><BR>Despite the recent decline in stock price, with a 1-month return of -14.81% compared to a Sensex return of 1.34%, the company's strong ROCE of 31.55% and a PEG ratio of 0.00 suggest that it is generating substantial returns on capital. However, given the overall market conditions and peer comparisons, Star Imaging remains overvalued in its current state.

Why is Star Imaging and Path Lab Ltd falling/rising?

As of 02-Jun, Star Imaging and Path Lab Ltd's stock price is currently Rs 70.00, down 3.45% with significant declines over various periods, including a year-to-date drop of 23.03%. The stock is underperforming its sector and shows bearish trends, with reduced investor participation and trading activity.

As of 02-Jun, Star Imaging and Path Lab Ltd's stock price is falling, currently at Rs 70.00, reflecting a decrease of Rs 2.5 or 3.45%. This decline is evident in the stock's performance over various periods, with a 1-week drop of 2.62% and a significant 1-month decrease of 10.78%. Year-to-date, the stock has fallen by 23.03%, which is notably worse than the Sensex's decline of 12.40% during the same timeframe.<BR><BR>Today's trading activity indicates that the stock has underperformed its sector by 3.43%. It reached an intraday low of Rs 68.91, marking a decrease of 4.95%. The weighted average price suggests that more trading volume occurred closer to this low price, indicating a lack of buying interest at higher levels. Additionally, there has been a notable decline in investor participation, with delivery volume on June 1 dropping by 75.9% compared to the 5-day average. This reduced activity further supports the downward pressure on the stock price.<BR><BR>While the stock is trading above its 50-day moving average, it remains below its 5-day, 20-day, 100-day, and 200-day moving averages, indicating a bearish trend in the short to medium term. Overall, these factors contribute to the ongoing decline in the stock price of Star Imaging and Path Lab Ltd.

Which are the latest news on Star Imaging?